Loading clinical trials...
Loading clinical trials...
Patients with myeloproliferative neoplasms (MPN) are predisposed to have an increased thrombotic and hemorrhagic risk and, in this context, the use of newly approved direct oral anticoagulants (DOACs)...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
NCT05564390 · Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, and more
NCT06859424 · AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), and more
NCT07270978 · Acute Myeloid Leukemia, Myelodysplastic Syndromes, and more
NCT06523556 · Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, and more
NCT03970096 · Acute Leukemia, Acute Lymphoblastic Leukemia, and more
Mount Sinai New York
New York, New York
Princess Margaret Cancer Centre Toronto
Toronto
Centre Hospitalier Universitaire de Brest
Brest
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions